Literature DB >> 32677464

Cytokine Levels and Symptoms Among Women with Irritable Bowel Syndrome: Considering the Role of Hormonal Contraceptive Use.

Kendra J Kamp1, Claire Han1, Robert J Shulman2, Kevin C Cain1, Pamela Barney1, Mark R Opp3, Lin Chang4, Robert L Burr1, Margaret M Heitkemper1.   

Abstract

BACKGROUND: Young to middle-aged women are more likely than men to be diagnosed with irritable bowel syndrome (IBS). Immune dysfunction may be present in IBS, however, few studies have tested whether hormonal contraceptive use is linked to inflammatory markers. The purpose of this study was to compare cytokine levels between women (ages 18-45) with and without IBS and with and without hormonal contraceptive use and to examine the relationships of cytokine levels to IBS gastrointestinal (GI) and non-GI symptoms within those using and not using hormonal contraceptives.
METHODS: Seventy-three women with IBS and 47 healthy control women completed questionnaires (demographics, hormonal contraceptive use) and kept a 28-day symptom diary. Fasting plasma and LPS-stimulated pro-inflammatory (IL-1β, IL-6, IL-12p40, IL-12p70, IL-8, and TNF-α) and anti-inflammatory (IL-10) cytokines were assayed.
RESULTS: No differences were found in plasma or stimulated cytokine levels between IBS and control women. Levels of IL-1β (p = 0.04) and TNF-α (p = 0.02) were higher among women who did not use hormonal contraceptives compared to women who used hormonal contraceptives. Among women with IBS, significant correlations were found between daily psychological distress and plasma IL-10, IL-12p70, IL-1β, IL-6, and IL-8 cytokine levels.
CONCLUSIONS: These results suggest that hormonal contraceptive use might reduce IL-1β and TNF-α cytokine levels in women with IBS. The impact of hormonal contraceptive use on innate immune activation among women with IBS requires further research.

Entities:  

Keywords:  contraception; cytokines; hormonal contraception; irritable bowel syndrome; symptoms

Mesh:

Substances:

Year:  2020        PMID: 32677464      PMCID: PMC8264855          DOI: 10.1177/1099800420941252

Source DB:  PubMed          Journal:  Biol Res Nurs        ISSN: 1099-8004            Impact factor:   2.522


  50 in total

1.  The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms.

Authors:  Kurt Kroenke; Robert L Spitzer; Janet B W Williams
Journal:  Psychosom Med       Date:  2002 Mar-Apr       Impact factor: 4.312

2.  Serum immune biomarkers in irritable bowel syndrome.

Authors:  Seyedmehdi Seyedmirzaee; Mohammad Mahdi Hayatbakhsh; Bizhan Ahmadi; Nadieh Baniasadi; Afshin Mohammad Bagheri Rafsanjani; Amin Reza Nikpoor; Mojgan Mohammadi
Journal:  Clin Res Hepatol Gastroenterol       Date:  2016-02-02       Impact factor: 2.947

3.  Symptoms across the menstrual cycle in women with irritable bowel syndrome.

Authors:  Margaret M Heitkemper; Kevin C Cain; Monica E Jarrett; Robert L Burr; Vicky Hertig; Eleanor F Bond
Journal:  Am J Gastroenterol       Date:  2003-02       Impact factor: 10.864

Review 4.  Role of estrogen and stress on the brain-gut axis.

Authors:  Yanyan Jiang; Beverley Greenwood-Van Meerveld; Anthony C Johnson; R Alberto Travagli
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-06-26       Impact factor: 4.052

5.  Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome.

Authors:  Robert J Shulman; Monica E Jarrett; Kevin C Cain; Elizabeth K Broussard; Margaret M Heitkemper
Journal:  J Gastroenterol       Date:  2014-01-17       Impact factor: 7.527

6.  Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors.

Authors:  Timothy G Dinan; Gerard Clarke; Eamonn M M Quigley; Lucinda V Scott; Fergus Shanahan; John Cryan; John Cooney; P W N Keeling
Journal:  Am J Gastroenterol       Date:  2008-09-10       Impact factor: 10.864

7.  Irritable bowel symptoms, use of healthcare, costs, sickness and disability pension benefits: A long-term population-based study.

Authors:  Chalotte H Poulsen; Lene F Eplov; Carsten Hjorthøj; Lene H Hastrup; Marie Eliasen; Thomas M Dantoft; Andreas Schröder; Torben Jørgensen
Journal:  Scand J Public Health       Date:  2018-05-01       Impact factor: 3.021

8.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

Review 9.  Sex hormones in the modulation of irritable bowel syndrome.

Authors:  Agata Mulak; Yvette Taché; Muriel Larauche
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

10.  Balance of Autonomic Nervous System Predicts Who Benefits from a Self-management Intervention Program for Irritable Bowel Syndrome.

Authors:  Monica E Jarrett; Kevin C Cain; Pamela G Barney; Robert L Burr; Bruce D Naliboff; Robert Shulman; Jasmine Zia; Margaret M Heitkemper
Journal:  J Neurogastroenterol Motil       Date:  2016-01-31       Impact factor: 4.924

View more
  1 in total

Review 1.  Gut bless you: The microbiota-gut-brain axis in irritable bowel syndrome.

Authors:  Eline Margrete Randulff Hillestad; Aina van der Meeren; Bharat Halandur Nagaraja; Ben René Bjørsvik; Noman Haleem; Alfonso Benitez-Paez; Yolanda Sanz; Trygve Hausken; Gülen Arslan Lied; Arvid Lundervold; Birgitte Berentsen
Journal:  World J Gastroenterol       Date:  2022-01-28       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.